Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial
Author:
Funder
European Union Framework
Publisher
Elsevier BV
Subject
Oncology,Hematology
Link
http://academic.oup.com/annonc/article-pdf/25/8/1544/16703237/mdu112.pdf
Reference39 articles.
1. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion;Schreiber;Science,2011
2. Lymphocyte infiltrates as a prognostic variable in female breast cancer;Aaltomaa;Eur J Cancer,1992
3. High expression of lymphocyte-associated genes in node-negative HER2+ breast cancers correlates with lower recurrence rates;Alexe;Cancer Res,2007
4. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer;Denkert;J Clin Oncol,2010
5. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy;Apetoh;Nat Med,2007
Cited by 1001 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Multiplexed high-throughput immune cell imaging in patients with high-risk triple negative early breast cancer: Analysis from the International Breast Cancer Study Group (IBCSG) Trial 22-00;European Journal of Cancer;2024-03
2. Investigating the role of tumour-to-skin proximity in predicting nodal metastasis in breast cancer;Breast Cancer Research and Treatment;2024-02-03
3. Ten-year clinical outcome, toxicity and compliance of dose-dense sequential adjuvant administration of cyclophosphamide & epirubicin followed by docetaxel in patients with early breast cancer: A hellenic cooperative oncology group observational study (HE 10/10) with concurrent investigation of significance of tumor infiltrating lymphocytes;The Breast;2024-02
4. Triple-Negative Breast Cancer Intrinsic FTSJ1 Favors Tumor Progression and Attenuates CD8+ T Cell Infiltration;Cancers;2024-01-31
5. High tumor infiltrating lymphocytes are significantly associated with pathological complete response in triple negative breast cancer treated with neoadjuvant KEYNOTE-522 chemoimmunotherapy;Breast Cancer Research and Treatment;2024-01-30
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3